Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    17451425 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Eze/Simva Switch Study in Diabetics (0653A-807)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks;   Drug: Comparator: atorvastatin / Duration of Treatment: 6 Weeks

Indicates status has not been verified in more than two years